Inhibrx

Inhibrx published interim results from the phase‑2 portion of the HexAgon study: the combination of INBRX-106 with pembrolizumab achieved a confirmed objective response rate of 44.0% versus 21.4% with pembrolizumab alone (absolute increase 22.6%). In the evaluable population, 11 of 25 patients in the combination arm responded, including three complete remissions, versus 6 of 28 in the control arm. Peripheral blood analyses showed up to 15‑fold increases in CD8+/CD4+ T‑cell proliferation with the combination versus up to 2.5‑fold with pembrolizumab alone; the safety profile was manageable. Inhibrx expects PFS data in Q4 2026 and plans to start the phase‑3 portion in Q3 2026. » Más en de.investing.com

Shares of Inhibrx Biosciences rose to $152.22, bringing market capitalization to about $1.23 billion after a year-to-date gain of more than 608%. Over the past six months the stock gained roughly 167% and is trading near its 52-week high, while InvestingPro rates the shares as overvalued relative to its fair-value estimate. The company reported interim results from the phase‑1/2 study of Ozekibart in combination with FOLFIRI in advanced colorectal cancer, showing an objective response rate of 20%, well above standard‑therapy rates. Despite the price gains, Inhibrx remains unprofitable (EPS -$9.04), and analysts such as Stifel maintain a buy rating with a $150.00 price target, highlighting the potential of INBRX-106. » Más en de.investing.com

Inhibrx has recruited 46 of 60 patients in the phase‑2 study of INBRX‑106 for head and neck cancer; study completion is expected in Q1 2026. Recruitment of 34 patients in the phase‑1/2 study of INBRX‑106 plus Keytruda in checkpoint‑inhibitor‑refractory non‑small cell lung cancer is complete, with meaningful data expected in H2 2026. The Ozekibart program showed a 52% reduction in the risk of progression or death in the ChonDRAgon study, sparking increased interest; additional Ozekibart data and ongoing recruitments are scheduled for 2026. Financially, the company operates with moderate debt and liquid assets that are exceeded by short‑term liabilities; if response rates persist, Inhibrx plans an FDA meeting in H2 2026. » Más en de.investing.com